Hypervector Spaces Based on Intersectional Soft Sets

The notion of int-soft subfields, int-soft algebras over int-soft subfields, and int-soft hypervector spaces are introduced, and their properties and characterizations are considered. In connection with linear transformations, int-soft hypervector spaces are discussed

Collective resonance modes of Josephson vortices in sandwiched stack of Bi2_{2}Sr2_{2}CaCu2_{2}O8+x_{8+x} intrinsic Josephson junctions

We observed splitting of the low-bias vortex-flow branch in a dense-Josephson-vortex state into multiple sub-branches in current-voltage characteristics of intrinsic Josephson junctions (IJJs) of Bi$_{2}$Sr$_{2}$CaCu$_{2}$O$_{8+x}$ single crystals in the long-junction limit. Each sub-branch corresponds to a plasma mode in serially coupled Josephson junctions. Splitting into low-bias linear sub-branches with a spread in the slopes and the inter-sub-branch mode-switching character are in good quantitative agreement with the prediction of the weak but finite inter-junction capacitive-coupling model incorporated with the inductive coupling. This suggests the importance of the role of the capacitive coupling in accurately describing the vortex dynamics in serially stacked IJJs.Comment: 4 pages, 3 figures, 1 tabl

Radion Dynamics and Phenomenology in the Linear Dilaton Model

We investigate the properties of the radion in the 5D linear dilaton model arising from Little String Theory. A Goldberger-Wise type mechanism is used to stabilise a large interbrane distance, with the dilaton now playing the role of the stabilising field. We consider the coupled fluctuations of the metric and dilaton fields and identify the physical scalar modes of the system. The wavefunctions and masses of the radion and Kaluza-Klein modes are calculated, giving a radion mass of order the curvature scale. As a result of the direct coupling between the dilaton and Standard Model fields, the radion couples to the SM Lagrangian, in addition to the trace of the energy-momentum tensor. The effect of these additional interaction terms on the radion decay modes is investigated, with a notable increase in the branching fraction to photons. We also consider the effects of a non-minimal Higgs coupling to gravity, which introduces a mixing between the Higgs and radion modes. Finally, we calculate the production cross section of the radion at the LHC and use the current Higgs searches to place constraints on the parameter space.Comment: 28 pages, 7 figures; v2: error in radion-gauge boson Feynman rules corrected, version published in JHE

Hypoxia mimetic agents for ischemic stroke

Every year stroke claims more than 6 million lives worldwide. The majority of them are ischemic stroke. Small molecule-based therapeutics for ischemic stroke has attracted a lot of attention, but none has been shown to be clinically useful so far. Hypoxia-inducible factor-1 (HIF-1) plays a crucial role in the transcriptional adaptation of cells to hypoxia. Small molecule-based hypoxia-mimetic agents either stabilize HIF-1α via HIF-prolyl hydroxylases (PHDs) inhibition or through other mechanisms. In both the cases, these agents have been shown to confer ischemic neuroprotection in vitro and in vivo. The agents which act via PHD inhibition are mainly classified into iron chelators, iron competitors, and 2 oxoglutarate (2OG) analogs. This review discusses HIF structure and key players in the HIF-1 degradation pathway as well as the genes, proteins and chemical molecules that are connected to HIF-1 and how they affect cell survival following ischemic injury. Furthermore, this review gives a summary of studies that used PHD inhibitors and other HIF-1α stabilizers as hypoxia-mimetic agents for the treatment of ischemic injury

Soft exosuits increase walking speed and distance after stroke

Finalist for best poster abstract and presentatio

Modulation of Mitochondrial Function and Autophagy Mediates Carnosine Neuroprotection Against Ischemic Brain Damage

Background and Purpose—Despite the rapidly increasing global burden of ischemic stroke, no therapeutic options for neuroprotection against stroke currently exist. Recent studies have shown that autophagy plays a key role in ischemic neuronal death, and treatments that target autophagy may represent a novel strategy in neuroprotection. We investigated whether autophagy is regulated by carnosine, an endogenous pleiotropic dipeptide that has robust neuroprotective activity against ischemic brain damage. Methods—We examined the effect of carnosine on mitochondrial dysfunction and autophagic processes in rat focal ischemia and in neuronal cultures. Results—Autophagic pathways such as reduction of phosphorylated mammalian target of rapamycin (mTOR)/p70S6K and the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II were enhanced in the ischemic brain. However, treatment with carnosine significantly attenuated autophagic signaling in the ischemic brain, with improvement of brain mitochondrial function and mitophagy signaling. The protective effect of carnosine against autophagy was also confirmed in primary cortical neurons. Conclusions—Taken together, our data suggest that the neuroprotective effect of carnosine is at least partially mediated by mitochondrial protection and attenuation of deleterious autophagic processes. Our findings shed new light on the mechanistic pathways that this exciting neuroprotective agent influences

Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients

BACKGROUND: Yellow fever vaccine (17DV) has been investigated incompletely in human immunodeficiency virus (HIV)-infected patients, and adequate immunogenicity and safety are of concern in this population. METHODS: In the Swiss HIV Cohort Study, we identified 102 patients who received 17DV while they were HIV infected. We analyzed neutralization titers (NTs) after 17DV administration using the plaque reduction neutralization test. NTs of 1:>or=10 were defined as reactive, and those of 1:<10 were defined as nonreactive, which was considered to be nonprotective. The results were compared with data for HIV-uninfected individuals. Serious adverse events were defined as hospitalization or death within 6 weeks after receipt of 17DV. RESULTS: At the time of 17DV administration, the median CD4 cell count was 537 cells/mm(3) (range, 11-1730 cells/mm(3)), and the HIV RNA level was undetectable in 41 of 102 HIV-infected patients. During the first year after vaccination, fewer HIV-infected patients (65 [83%] of 78; P = .01) than HIV-uninfected patients revealed reactive NTs, and their NTs were significantly lower (P < .001) than in HIV-uninfected individuals. Eleven patients with initially reactive NTs lost these reactive NTs <or= 5 years after vaccination. Higher NTs during the first year after vaccination were associated with undetectable HIV RNA levels, increasing CD4 cell count, and female sex. We found no serious adverse events after 17DV administration among HIV-infected patients. CONCLUSION: Compared with HIV-uninfected individuals, HIV-infected patients respond to 17DV with lower reactive NTs, more often demonstrate nonprotective NTs, and may experience a more rapid decline in NTs during follow-up. Vaccination with 17DV appears to be safe in HIV-infected individuals who have high CD4 cell counts, although rate of serious adverse events of up to 3% cannot be exclude

The Potential of Adaptive Design in Animal Studies

Clinical trials are the backbone of medical research, and are often the last step in the development of new therapies for use in patients. Prior to human testing, however, preclinical studies using animal subjects are usually performed in order to provide initial data on the safety and effectiveness of prospective treatments. These studies can be costly and time consuming, and may also raise concerns about the ethical treatment of animals when potentially harmful procedures are involved. Adaptive design is a process by which the methods used in a study may be altered while it is being conducted in response to preliminary data or other new information. Adaptive design has been shown to be useful in reducing the time and costs associated with clinical trials, and may provide similar benefits in preclinical animal studies. The purpose of this review is to summarize various aspects of adaptive design and evaluate its potential for use in preclinical research